ACADIA PHARMACEUTICALS INC
Acadia Pharmaceuticals is a biopharmaceutical company focused on neurological and rare diseases, with global headquarters in San Diego, California. It sells NUPLAZID (pimavanserin), approved in the United States for hallucinations and delusions associated with Parkinson’s disease psychosis, and DAYBUE (trofinetide), approved for Rett syndrome. DAYBUE STIX is a powder formulation for oral solution for Rett syndrome. Acadia earns money from sales of its commercial products and has worldwide commercialization rights to NUPLAZID. It also holds rights to develop and commercialize trofinetide outside North America. The company develops product candidates and conducts research programs in neurological and rare diseases. Its pipeline includes remlifanserin for Alzheimer’s disease psychosis and Lewy Body Dementia Psychosis, ACP-211 for major depressive disorder, ACP-711 for essential tremor, ACP-271 for tardive dyskinesia and Huntington’s disease, and ACP-2591 for Rett syndrome and Fragile X syndrome. Acadia also collaborates with Stoke Therapeutics on RNA-based medicines for severe and rare genetic neurodevelopmental diseases.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Morgan Stanley reduced its price target for ACADIA Pharmaceuticals (ACAD) to $24 from $28, while maintaining an Equal-Weight rating. The average 12-month price target among analysts decreased to $30.11, with a Buy consensus.
ACADIA Pharmaceuticals (ACAD) has an average 12-month price target of $30.33, down from $30.53, based on 18 analysts. The consensus rating is Buy, with 15 Buy, 4 Hold, and 1 Sell. The target is 67% above its Nov. 12 close, according to TradingView.
Acadia Pharmaceuticals (ACAD) shares rose after an appeal court heard arguments on a patent dispute over Nuplazid, its lead product. The case challenges a lower court's decision to uphold a key U.S. patent related to the drug.
Over the past 7 days, AlphAI's AI scored 5 news stories mentioning ACAD (ACADIA PHARMACEUTICALS INC). Coverage has skewed bearish: 1 bullish, 2 neutral, and 2 bearish.
Recent ACAD coverage spans earnings, financial news and regulation.
In the last 30 days, ACAD insiders filed 1 SEC Form 4 transaction — no purchases and 1 sale ($69K). The most active reporter was Schneyer Mark C., EVP, CHIEF FINANCIAL OFFICER, with 1 filing. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Analyst target reduction suggests lower near‑term upside.
The target cut suggests slightly weaker outlook, likely pressuring the stock modestly.
The oral arguments suggest a potential favorable outcome for Acadia, supporting its patent rights.
Guidance cut and trial risk drive immediate sell pressure.
Street valuation for ACAD is revised upward via a higher PT while rating stays Buy, which can support near-term sentiment and positioning.
AlphAI scores every news story that mentions ACAD with an AI model for sentiment and relevance, and aggregates insider trades from ACADIA PHARMACEUTICALS INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
Morgan Stanley reduced its price target for ACADIA Pharmaceuticals (ACAD) to $24 from $28, while maintaining an Equal-Weight rating. The average 12-month price target among analysts decreased to $30.11, with a Buy consensus.
ACADIA Pharmaceuticals (ACAD) has an average 12-month price target of $30.33, down from $30.53, based on 18 analysts. The consensus rating is Buy, with 15 Buy, 4 Hold, and 1 Sell. The target is 67% above its Nov. 12 close, according to TradingView.
Acadia Pharmaceuticals (ACAD) shares rose after an appeal court heard arguments on a patent dispute over Nuplazid, its lead product. The case challenges a lower court's decision to uphold a key U.S. patent related to the drug.
Acadia Pharmaceuticals (ACAD) reduced its 2026 R&D guidance to $355M-$380M, maintaining $956M in cash. Its stock fell 22% in a day and 44% in 90 days, despite analysts estimating a fair value of $30.53, suggesting 46% undervaluation. The company's future hinges on trial results and sales of DAYBUE and NUPLAZID.
Canaccord Genuity reaffirmed its Buy rating for Acadia Pharmaceuticals and increased its price target to $38 from $36, citing a 78.9% upside potential from the recent close of $21.24. Other recent analyst price targets for the company range from $23 to $38.
RBC Capital raised its price target for Acadia Pharmaceuticals (ACAD) to $38, citing strong Daybue uptake and growth potential. The firm expects European launch and pipeline readouts to drive future sales. Acadia reported Q3 2026 earnings of $0.31 per share, beating estimates, with revenue of $342 million. Daybue sales grew 39% YoY to $140 million, while Nuplazid sales increased 12% to $202 million. The company narrowed its 2026 revenue guidance to $1.265B-$1.295B.
ACADIA Pharmaceuticals (ACAD) reported Q3 earnings, highlighting a U.S. patent extension for DAYBUE until 2041. NUPLAZID sales grew 12% to $202M, with full-year guidance narrowed to $760M-$775M. The company expects $1.265B-$1.295B in 2026 revenue. R&D expenses fell to $76M, while SG&A rose to $159M. ACADIA remains confident in a NUPLAZID patent appeal and plans to refine its remlifanserin trial for Alzheimer's disease psychosis.
ACADIA Pharmaceuticals (ACAD) reports Q3 earnings on November 4, 2026. Analysts expect $0.20 EPS and $332.42M revenue. Stock has a 'Moderate Buy' consensus with a $30.53 price target. Investors focus on DAYBUE and NUPLAZID sales growth and remlifanserin development updates. EMA recommended marketing authorization for DAYBUE in the EU.
AcadeMedia AB (publ) reported Q1 net sales of SEK 4,679M, up 14.1% YoY, with organic growth of 4.8%. Adjusted EBITA was SEK 215M, up from SEK 182M a year earlier, with a margin of 4.6% vs 4.4%.
The Cambridgeshire and Peterborough NHS Foundation Trust launched AD-SMART, a UK trial testing multiple Alzheimer treatments simultaneously. Cognition Therapeutics aligned with the FDA on a phase 3 trial of zervimesine for dementia with Lewy bodies. Neurocrine Biosciences initiated a phase 2 study of NBI-'567 for Alzheimer disease. Acadia Pharmaceuticals reported phase 2 results for remlifanserin in Alzheimer disease psychosis.
